A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.

Phase

Condition

Chronic Pain

Pain

Treatment

N/A

Clinical Study ID

NCT00347685

B00.CTOL.003.TRA P03

Ages > 18
All Genders

Study Summary

The purpose of this study is to assess the safety of tramadol HCl ER following long-term treatment. The study hypothesis is that long-term treatment with tramadol HCl ER is safe and effective for the treatment of chronic, non-malignant pain.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients with a history of chronic, non-malignant pain >= 6 months requiring treatmentwith an analgesic; females of childbearing potential practicing abstinence or amedically accepted form of contraception with a negative serum pregnancy test within 7days of study entry; patients able to understand the procedures, complete the painscales and able to communicate meaningfully with study personnel; patients who agreeto study participation and sign a form indicating their informed consent.

Exclusion

Exclusion Criteria:

Patients with an uncontrolled medical condition; patients whose weight <= 100 pounds;patients with dysphagia or difficulty swallowing tablets; patients with intractablenausea and vomiting; patients with a history of clinically significant intolerance totramadol or a known hypersensitivity to opioid analgesics, such that treatment withtramadol or other opioids is contraindicated.

Study Design

October 01, 2000

February 28, 2003

Study Description

Immediate release (IR) tramadol has demonstrated efficacy in several pain conditions including: obstetrical, gynecological, orthopedic, abdominal, and oral surgery. The short elimination half-life of IR tramadol necessitates every 4-6 hour dosing to maintain optimum levels of analgesia in chronic pain. The study medication in this study is a once-daily, extended release (ER) tramadol formulation. This study is a multicenter, multiple-dose, 1-year open-label study designed to assess the safety and effectiveness of tramadol HCl ER. Patients with moderate to severe chronic non-malignant pain, requiring treatment with an analgesic on a daily basis, are eligible for study participation. Patients eligible for enrollment are as follows: those who completed 12 weeks in one of two prior double-blind studies ("roll-over patients") or those without participation in any prior study of tramadol HCl ER ("direct enrollment patients"). Following a screening evaluation and baseline assessment, roll-over patients will be treated for up to 38 weeks and direct enrollment patients for up to 58 weeks. At baseline (Visit 2), patients will receive tramadol HCl ER 100 mg once daily (QD) for 3 days; on day 4, they will increase to tramadol HCl ER 200 mg QD, based on tolerability. Patients will be required to be on a minimum dose of tramadol HCl ER 200 mg QD by Visit 3. At Visit 4, patients are required to begin treatment with a minimum dose of tramadol HCl ER 300 mg QD. The maximum dose of tramadol HCl ER for patients >= 75 years old is 300 mg QD. By Visit 5, patients < 75 years old are to be initiated on a tramadol HCl ER dose of 400 mg QD. Patients who cannot tolerate a dose increase of tramadol HCl ER from 300 mg or 400 mg QD (due to side effects) or who upon dose increase cannot tolerate the dose will be permitted to reduce the tramadol HCl ER dose to 300 mg QD. Patients unable to tolerate tramadol HCl ER 300 mg or 400 mg QD or those who had pain unresponsive to appropriate dose adjustments will be discontinued and alternate analgesic therapy initiated, as appropriate.

Connect with a study center

Gainesville Clinical Research Center
Gainesville, Florida 32605
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.